Study: Redefining the criteria for ALK positive lung cancer
September 10, 2013 · Comments Off
A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug.
With early and obvious benefit of a targeted cancer drug, should expensive clinical testing continue?
August 8, 2013 · Comments Off
When a drug's benefit is obvious in a clinical trial's first or second phase, is the third, costly phase needed? The question is posed in a recent edition of the journal Nature Reviews: Clinical Oncology by Robert C. Doebele, MD, PhD, investigator at the University of Colorado Cancer Center and assistant professor of medical oncology at the CU School of Medicine.
Reality TV meets reality for lung cancer treatment
June 6, 2013 · Comments Off
By Todd Neff It was Memorial Day Weekend 2012, and Ross Camidge, MD, PhD, was...
Multicenter international study confirms low testosterone in 84 percent of lung cancer patients taking crizotinib
April 17, 2013 · Comments Off
Ross Camidge, MD, PhD, and international colleagues confirm low testosterone in a majority of lung cancer patients treated with crizotinib.
Lung cancer patients developing areas of drug-resistance prolong disease control by using focused radiation to weed the garden
November 28, 2012 · Comments Off
KEY POINTS: Pockets of cancer may mutate to gain resistance to targeted therapies It’s possible...
Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test
August 28, 2012 · Comments Off
Almost exactly a year ago, the FDA approved the drug crizotinib to treat these ALK+ lung cancer patients, who were likely never smokers. Informed doctors use the test called a FISH assay to check for the EML4-ALK fusion gene, and then if the test is positive, ALK+ patients benefit greatly from crizotinib.
Chromosomal translocations point the way toward personalized cancer care
August 13, 2012 · Comments Off
A broken chromosome is like an unmoored beansprout circling in search of attachment. If a...
Weeding the garden zaps pockets of crizotinib-resistant lung cancer
June 5, 2012 · Comments Off
The drug crizotinib targets ALK-positive non-small cell lung cancer (NSCLC) and erlotinib targets EGFR-dependent NSCLC....
ALK-positive lung cancer develops crizotinib resistance – now what?
June 4, 2012 · Comments Off
In 2011, the drug crizotinib was approved for use with the subset of non-small cell...
NTRK1: a new oncogene and target in lung cancer
June 4, 2012
alk drug lung cancer amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno biomarkers bladder cancer breast cancer cancer grants cancer research colorado Cancer Survivorship clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma metastasis microRNA Monique Spillman Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge screening skin cancer Thomas Flaig tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
New tool developed at the CU Cancer Center helps doctors identify patients at highest risk of mortality --... http://t.co/RG1VMhAfyo
If you were planning to attend either our brain tumor support group at University of Colorado Hospital or our... http://t.co/Wsbl49jxag
New Cancer Center study shows active component of grape seed extract effective against cancer cells. http://t.co/nq2Cfar6an
C3 Magazine: Collaborating to Conquer Cancer Fall edition is here. Read stories about fingerprinting cancer, a... http://t.co/ce9xjCSHBi